Johnson & Johnson’s Akeega (niraparib and abiraterone acetate dual action tablet) could soon be available to EU patients with metastatic hormone-sensitive prostate cancer with BRCA1/2 mutations, following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP). The recommendation is for niraparib and abiraterone acetate with prednisone or prednisolone (AAP) in combination […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!